WEST FARGO, N.D.–(BUSINESS WIRE)–GreenMan Vision, Inc. today announced the publication of a peer-reviewed, multi-center study evaluating InSightVR, a patient-specific VR platform that helps cataract patients experience simulated vision with different…
Author: Business Wire
Autobahn Therapeutics Reports AMPLIFY-BD Results for Elunetirom in Bipolar Depression, Highlighting Rapid, Robust, and Sustained Improvements in Depressive Symptoms and Functioning
SAN DIEGO–(BUSINESS WIRE)–Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that full results from its Phase 2 AMPLIFY-BD trial were presented at …
AlphaLum Appoints AR Display Pioneer Antti Sunnari to Board of Directors and Welcomes Former Meta Optics Leader Barry Silverstein as Advisor
LAUSANNE, Switzerland–(BUSINESS WIRE)–AlphaLum, a Swiss AI optics and sensing startup, appoints Antti Sunnari (Dispelix CEO) to its Board and Barry Silverstein (ex-Meta) as Advisor.
Science Corporation Names Darius Shahida as President
ALAMEDA, Calif.–(BUSINESS WIRE)–Science Corporation, the neural engineering and brain-computer interface company, today announced the appointment of its Chief Strategy Officer, Darius Shahida, as President, effective immediately. Shahida will continu…
Sling Therapeutics Announces First Patients Dosed in Global Phase 3 ORBIT Pivotal Trial of Linsitinib for Thyroid Eye Disease
ANN ARBOR, Mich.–(BUSINESS WIRE)–Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the first patients have been dos…
Sling Therapeutics Announces $123 Million Series C Financing to Advance Phase 3 Development of its Oral Small Molecule IGF-1R Inhibitor for Thyroid Eye Disease
ANN ARBOR, Mich.–(BUSINESS WIRE)–Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the close of a $123 million Seri…
Simon Eye Expands Pennsylvania Footprint Through Partnership With Ganly Vision Care
KENNETT SQUARE, Pa.–(BUSINESS WIRE)–Simon Eye Associates (“Simon Eye”), a growing regional provider of comprehensive and advanced eye care, has partnered with Ganly Vision Care in Kennett Square, Pennsylvania, effective September 14, 2026. The partne…
Eyexora to Host Two-Part Key Opinion Leader Webinar Series
NEW YORK & SINGAPORE–(BUSINESS WIRE)–Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, today announced that it will host a key opinion leader (KOL) webinar series featuring globally reco…
Stuart Therapeutics, Inc. to Present at the Citizens Private Ophthalmology Summit
STUART, Fla.–(BUSINESS WIRE)–Stuart Therapeutics, Inc. (“Stuart”), a late-stage biopharmaceutical company developing a new class of therapeutics designed to repair helical collagen for the treatment of eye diseases, today announced that Eric Schlumpf…
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLyra, the company’s next generatio…
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
NEW HAVEN, Conn.–(BUSINESS WIRE)–Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the pricing of…
حصول Johnson & Johnson على علامة CE للعدسات اللاصقة القابلة لإعادة الاستخدام ACUVUE OASYS MAX
ليمريك، أيرلندا–(BUSINESS WIRE)–أعلنت اليوم شركة Johnson & Johnson (بورصة نيويورك: JNJ) عن حصولها على علامة CE للعدسات اللاصقة ACUVUE OASYS MAX 2-Week،*** وهي عدسات لاصقة جديدة قابلة لإعادة الاستخدام، تتميز بتقنيات MAX المملوكة للشركة والمصممة لت…
Resumen: Johnson & Johnson obtiene el marcado CE para las lentillas reutilizables ACUVUE OASYS MAX
LIMERICK, Irlanda–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) anunció hoy la obtención del marcado CE para ACUVUE OASYS MAX 2-Week,*** unas nuevas lentillas reutilizables que incluyen las tecnologías patentadas MAX, diseñadas para ofrecer una c…
Johnson & Johnson reçoit le marquage CE pour les lentilles de contact réutilisables ACUVUE OASYS MAX
LIMERICK, Irlande–(BUSINESS WIRE)–Johnson & Johnson (NYSE : JNJ) annonce aujourd’hui avoir reçu le marquage CE pour ACUVUE OASYS MAX 2-Week,*** une nouvelle lentille de contact réutilisable dotée de technologies MAX exclusives conçues pour offrir…
Samenvatting: Johnson & Johnson ontvangt CE-markering voor herbruikbare ACUVUE OASYS MAX-contactlenzen
LIMERICK, Ierland–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) heeft vandaag aangekondigd dat het de CE-markering heeft ontvangen voor ACUVUE OASYS MAX 2-Week,*** een nieuwe herbruikbare contactlens met eigen MAX-technologieën, ontworpen voor su…
Riassunto: Johnson & Johnson riceve il marchio CE per le lenti a contatto riutilizzabili ACUVUE OASYS MAX
LIMERICK, Irlanda–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) oggi ha annunciato di aver ricevuto il marchio CE per ACUVUE OASYS MAX 2-Week,*** una nuova lente a contatto riutilizzabile basata su tecnologie proprietarie MAX progettate per garan…
Johnson & Johnson erhält CE-Kennzeichnung für wiederverwendbare Kontaktlinsen der Marke ACUVUE OASYS MAX
LIMERICK, Irland–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) gab heute bekannt, dass das Unternehmen die CE-Kennzeichnung für ACUVUE OASYS MAX 2-Week*** erhalten hat, eine neue wiederverwendbare Kontaktlinse mit proprietären MAX-Technologien, d…
Yarrow Bioscience Announces Proposed Underwritten Public Offering
NEW HAVEN, Conn.–(BUSINESS WIRE)–Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced that it has co…
Eyexora to Participate in the Citizens Virtual Private Ophthalmology Summit
NEW YORK & SINGAPORE–(BUSINESS WIRE)–Eyexora, a biotech company pioneering innovative therapies for ophthalmic diseases through a hub-and-spoke model, today announced that Theresa Heah, MD, MBA, Chief Executive Officer and Vice Chair, will participat…
Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
LIMERICK, Ireland–(BUSINESS WIRE)–Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX 2-Week, a new reusable contact lens featuring proprietary MAX technologies.